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Recombinant RNA technology : The tRNA scaffold 
Luc Ponchon, Frédéric Dardel 
Cristallographie & RMN Biologiques, Université Paris Descartes, CNRS, 4 avenue de l'Observatoire, 75006, Paris, 
France. Correspondance to F.D. (frederic.dardel@univ-paris5.fr) 
During the past decades, RNA has emerged as a major player in most cellular processes. 
Understanding these processes at the molecular level requires homogeneous RNA 
samples for structural, biochemical and pharmacological studies. So far, this has been a 
bottleneck, as the only methods for producing such pure RNA were in vitro syntheses. 
Here, we describe a generic approach for expressing and purifying structured RNA in E. 
coli, using a series of tools which parallel those available for recombinant proteins. Our 
system is based on a camouflage strategy, the “tRNA scaffold”, in which the recombinant 
RNA is disguised as a natural RNA and thus hijacks the host machinery, escaping cellular 
ribonucleases. This opens the way to large scale structural and molecular investigations 
of RNA function. 
Introduction 
Systematic studies of protein structure, function and interactions such as structural genomics 
and double-hybrid approaches have greatly benefited from the development of efficient 
recombinant expression systems. Simultaneously, new roles have been evidenced for 
structured RNA in translation, chromosome maintenance, viral replication, as riboswitches or 
ribozymes1-3. As a result, these RNA are considered as promising drug targets, as for instance 
bacterial rRNA (antibiotics) or telomerase RNA4. Owing to their large structural repertoire, 
folded RNA are also interesting molecules for constructing self-assembling nano-objects, some 
of which have been used for delivering therapeutic siRNA5,6. As opposed to proteins, 
systematic biochemical, structural and pharmacological studies of RNA have however been 
hampered by difficulties in obtaining homogeneous samples in large quantities. So far, RNA 
has mostly been produced in vitro using either T7 RNA polymerase transcription7 or chemical 
synthesis8, which are costly and cumbersome. Producing recombinant RNA in vivo could be an 
alternative, but thus far has been plagued by a number of obstacles, such as heterogeneity of 
the products, degradation by ribonucleases and difficulty in purifying the RNA from cell 
extracts. For example, RNA transcripts overexpressed in vivo using the T7 system9 are long 
and heterogeneous, as a consequence of terminator read-through, and have never been 
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purified. 5S ribosomal RNA10 and tRNA11-14 are two exceptions which have been successfully 
expressed in E. coli. In the latter case, it works because tRNA are recognized by cellular 
enzymes that precisely process the primary transcript, incorporate modified nucleotides and 
repair their 3'-end15. This results in a single product of defined length, a key feature for 
structural studies. Furthermore, tRNA adopt a compact 3D structure which makes them 
resistant to both unfolding and nucleases.  
We used this robustness and precise processing to express other structured RNA in vivo and 
designed a generic method using tRNA as a protective scaffold. We extracted the desired 
recombinant RNA with high yield and purified it to homogeneity using standard 
chromatography. We employ tools for tagging the RNA with affinity or fluorescent aptamers 
and present a scheme for efficiently cleaving off the tags. Overall, the set of methods described 
here offers in vivo tools for the RNA world which were up to now only available for 
recombinant proteins. 
Results 
The tRNA scaffold approach 
We first tried to directly express structured RNA such as aptamers with vectors 
previously shown to work with tRNA. However,  the resulting transcripts were heterogeneous 
and failed to accumulate at a significant level. Hence it is the tRNA structure, rather than the 
vector that allows stable expression. Based on this finding we constructed tRNA-RNA fusions, 
similar to GST fusions used for protein expression. In order to retain the 3D structure of the 
tRNA that is recognized by cellular factors, it was necessary to keep the acceptor, TΨC and D 
stems (Fig. 1a). This left the anticodon stem as a region for inserting the desired RNA. The 
resulting RNA chimeras are expected to be recognized by tRNA processing enzymes. Indeed, 
bacteria naturally produce such a tRNA chimera, transfer-messenger RNA (tmRNA), 
involved in trans-translation, a rescue mechanism for ribosomes trapped on defective 
messenger RNA16. tmRNA carries a tRNA-like domain17 with a large, complex structure 
inserted in the lower stem. Since tmRNA is known to be efficiently processed by tRNA 
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specific factors, it seemed reasonable to assume that an artificially engineered chimera using 
such a tRNA scaffold would be similarly handled by bacterial cells, in much the same way as 
intron-containing tRNA are processed in eukaryotes. 
We therefore constructed various plasmids for expressing such recombinant RNA. The 
anticodon stem-loop was replaced by a sequence containing restriction sites, designed to 
maintain the 2D structure (Fig. 1b). Two tRNA scaffolds were used: human tRNALys3  and E. 
coli tRNAMet. We selected these because NMR assignments of both tRNAs have been 
reported, and they have been shown to be efficiently expressed in a recombinant system13,14. 
Also, the availability of two different scaffolds is advantageous in cases where RNA misfolding 
occurs because of spurious complementarity between the tRNA and the inserted sequence. 
Figure 1b shows the schematic organization of the corresponding expression vectors (DNA 
sequence in Supplementary Fig. 1). In principle, any structured RNA terminated by a 
stem could thus be inserted into the tRNA scaffold, including aptamers, ribozymes, viral RNA 
sequences. 
Producuction and characterization of a tRNA chimera 
As a test case, we focused on the epsilon sequence of human hepatitis B virus (HBV)18,19. 
This RNA consists of two stems separated by a bulge on which reverse transcription initiates. 
We expressed chimeras with both tRNALys3 (Fig. 1c) and tRNAMet scaffolds. The 
corresponding RNA (112 nucleotides) is strongly expressed by the recombinant strains, 
representing about 20% of total RNA and roughly 60% of all small, tRNA-size molecules. As 
described under Methods, the tRNA chimera can be easily visualized by performing RNA 
“minipreps” from small scale overnight cultures. Alternatively, this RNA can be purified on a 
larger scale by standard chromatography (Fig. 1d). Typical yields are 10-50 mg of purified 
RNA per liter. By growing cells in labeled medium, it is possible to enrich the recombinant 
RNA with stable isotopes, such as 15N and 13C and to confirm by NMR that the RNA is 
correctly folded: the 1H-15N TROSY spectrum of the chimeric RNA (Fig. 2) shows a number 
of well resolved peaks, indicative of a defined, folded structure. We could unambiguously 
assign most of these peaks to either the tRNALys3 or the HBV epsilon parts. In addition, the 
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spectra show that the tRNA chimera contains modified nucleotides: they show a number of 
characteristic shifted resonances (Fig. 2): ribothymidine (rT), pseudouridine (Ψ), 7-
methylguanosine (m7G), 4-thiouridine (s4U). Hence, in vivo, this fused construct is recognized 
as a genuine tRNA by the cell. It is correctly processed to a single species of defined length 
and is modified at expected sites by structure-specific enzymes. Modified nucleotides are 
known to stabilize the tertiary fold of tRNA, in addition, some of them (e.g. s4U at position 8) 
can provide convenient reactive groups for covalently attaching fluorescent labels or 
immobilizing RNA on solid support20.  
Applicability of the tRNA scaffold approach 
We evaluated the general applicability of the method by constructing a series of 
chimeras and testing for their expression in vivo. We selected a number of diverse inserts, 
varying in size, topology of the secondary structure, biological origin and function (Fig. 3). 
Over twenty such constructs have been tested, corresponding to chimeras ranging from 74 to 
376 nucleotides in length (Fig. 3 and Supplementary Fig. 2). For inserts corresponding to 
structured RNA domains, all the chimera were efficiently expressed and processed to a 
product of defined length (Fig. 4a). This was independent of the origin of the RNA insert: 
artificial, viral, bacterial and human sequences were all efficiently produced and both 
branched and nested stem-loop structures were apparently well expressed by the system (yields 
are given in Supplementary Table 1). Some inserts nevertheless failed to be expressed, for 
instance, a construct containing the template region of the human telomerase RNA yielded no 
detectable product. This is possibly because it contained single-stranded regions which led to 
nuclease degradation in vivo. Longer inserts also gave smaller yields, suggesting that complex 
domains might occasionally  misfold and get degraded. In order to minimize this problem, all 
tentative constructs were submitted to a computer prediction of their 2D structure. 
In order to test the function of these recombinant molecules, we first analyzed a number 
of ligand-binding RNAs, such as the aptamer selected against sephadex21 (Supplementary 
Fig. 2). The corresponding RNA could be bound to sephadex G100, directly from whole cell 
extracts and further eluted with soluble dextran (Fig. 4b). We obtained similar results with 
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aptamers selected against streptavidin22  or malachite green23 (Supplementary Fig. 3). We 
also tested the ability of several recombinant constructs to spontaneously self-assemble and 
form oligomers: the dimerization initiation site (DIS) of HIV-1 genomic RNA24 induces 
dimerization of the corresponding chimera (Supplementary Fig. 4), as in the viral context. 
Similar results were obtained with the chimera containing the pre-head RNA of 
bacteriophage φ29 (Supplementary Fig. 2), a structural  RNA that self-assembles into a 
ring structure required for packaging the viral DNA25,26. We performed all the above assays 
using the entire tRNA scaffold chimeras, indicating that within the tRNA context, the inserted 
RNA are correctly folded and functional. 
Affinity tags and pull-down assay 
In order to enhance the capabilities of the system and streamline purification, we 
constructed expression vectors allowing the expression of tripartite chimeras containing both 
an sephadex aptamer-based affinity tag and the RNA of interest inserted in the tRNA 
scaffold. We made combined constructs for duck and human HBV epsilon RNA (Fig. 3c), 
and for an E. coli 23S rRNA fragment (Supplementary Fig. 2) and used the sephadex 
affinity tag to purify the expressed RNA directly from cell lysates under native conditions, in 
the presence of proteins (Fig. 4b). Since the tRNA chimeras are folded correctly and 
functional within cells, they can be used for in vivo studies. By immobilizing RNA chimeras on 
the affinity matrix, it is possible to perform specific pull down assays, e.g. the  specific binding 
of ribosomal protein L20 to its target site on the 23S rRNA27 (Fig. 4c). We also derived 
similar constructs with a different topology from the streptavidin aptamer (Supplementary 
Fig. 2). 
Release of the RNA insert from the tRNA scaffold 
Although for some studies, the entire RNA chimera might be acceptable or even 
beneficial, in other cases it might be preferable to cleave the desired RNA off the scaffold. 
Several strategies were considered: using either a dedicated ribozyme or DNAzyme, or 
cleaving with RNAse H using a pair of guide DNA oligonucleotides. Dual cis-acting ribozyme 
constructs have been used for in vitro transcribed RNA, but this approach is not compatible 
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with the tRNA scaffold topology28. In our hands, the method that worked best is RNAse H 
cleavage (Fig. 4d). It produces a defined product in a quantitative manner, furthermore, 
guide oligonucleotides for RNAse H cleavage are targeted against the constant part of the 
scaffold and hence, the same pair can be used for all constructs. Previous reports of specific 
RNA cleavage using RNAse H used modified DNA nucleotides29 to improve specificity. In 
the present case, we used standard DNA oligonucleotides and obtained a single defined 
product. In order to test the yield and purity using this method, a large scale preparation was 
performed, using a tRNA chimera carrying the bacterial 16S ribosomal RNA A-site 
(Supplementary Fig. 2). Approximately 0.8 µmole of doubly labeled RNA was obtained 
from 2 liters of 15N/13C labeled medium. The recombinant product was 33 nucleotides long,  
with cleavage sites located at the junction of the cloverleaf structure (Fig. 5). This could be a 
consequence of the GC-richness of the top of the anticodon-like stem which would resist 
strand displacement by the ends of the DNA oligonucleotides. 
We analyzed this purified labeled RNA by gel electrophoresis (Supplementary Fig. 5) 
and by NMR. A typical 15N-1H experiment is shown in Figure 5, revealing the NH imino 
groups involved in base pairing. The NMR spectrum shows a unique set of peaks, a direct 
evidence that a single product with a unique conformation is present in the sample. It also 
shows the presence of one A-U and ten to eleven G-C base pairs, in keeping with the 
predicted secondary structure. This RNAse H cleavage strategy has now been successfully 
applied to six different constructs with the same guide DNA oligonucleotides. In all cases, 
quantitative cleavage was observed, suggesting that it is a broadly applicable method.  
Discussion 
In the present work, we demonstrate that it is possible to use this tRNA scaffold approach to 
express a large range of RNA chimera. The bacterial machinery recognizes and processes 
these constructs to single species which accumulate stably within the transformed cells. This 
demonstrates that, as postulated at start,  the tRNA structure is robust and can accommodate 
and protect RNA inserts with diverse sizes and structures (Fig. 3). In all tested cases, the 
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recombinant RNA were folded and functional, even within the chimera. The tRNA scaffold 
approach is thus a broadly applicable strategy for producing large quantities of virtually any 
structured RNA fragment. The procedures are all straightforward, involving only standard 
and parallelizable techniques. The objectives were to make it possible to express any RNA or 
collection of RNA fragments in a matter of a few days. For instance, construction of the 
recombinant expression plasmids is extremely simple: for small RNA inserts, it suffices to 
ligate a pair of complementary DNA oligonucleotides in the selected vector. It should thus be 
possible to produce libraries of relevant RNA fragments, such as aptamers or non coding 
RNA, for systematic functional analyses.  
Several RNA fragments produced and purified in this work are of major 
pharmacological interest : Domain III of hepatitis C virus internal ribosome entry site, the 
epsilon sequence of human and duck HBV viruses, HIV-1 genomic RNA fragments, domains 
CR4-CR5 and H/ACA of human telomerase RNA and antibiotic binding regions of bacterial 
ribosomal RNA (Constructs shown in Supplementary Fig. 2). Tens of milligram quantities 
of pure and stable RNA could thus be reproducibly obtained from liter-scale cultures. Such 
amounts are required to perform large scale screening of pharmacologically active compounds 
targeting RNA or for large scale production of “therapeutic” RNA constructs. Screening for 
ligands specific of these RNA targets using flow-injection NMR30 is currently under way. 
Generic purification procedures using affinity tags should open the way to a new range 
of applications: systematic structural approaches, both by NMR and by crystallography, high 
throughput parallel studies of RNA-protein interactions and combinatorial strategies. In 
addition, it should now be possible to perform novel in vivo approaches, such as co-expression 
of RNA-protein complexes. The recombinant RNA approach is also cost effective, which is 
important for studies requiring incorporation of expensive stable isotopes, and for applications 
requiring large amounts of material, such as medium and high-throughput screening of RNA-
specific ligands. For the latter applications, however cleavage of the target RNA from the 
scaffold is likely to be required to eliminate tRNA binding-ligands, at least in secondary 
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screens. With the availability of fluorescent tags, and an efficient generic cleavage system, the 
complete spectrum of tools available for recombinant proteins is now also available for RNA. 
 
Methods 
Vector construction. We derived all vectors from pBSTNAV12, by assembling synthetic 
overlapping oligonucleotides (purchased from Eurogentec). We constructed six such vectors, 
based on either human tRNALys3 or E. coli tRNAMet, using either no tag, a streptavidin or a 
sephadex aptamer tag. We subsequently used these vectors for inserting the various DNA 
oligonucleotides coding for the RNA fragments using a similar strategy (Fig. 1b). The DNA 
sequence of all plasmid constructs was checked (Millegen, France). The cloning sites are EagI 
(5’) and SacII (3’) for the naked scaffold vectors and SalI (5’) and AatII (3’) for the aptamer 
containing vectors (Supplementary Fig. 1). 
RNA expression and purification. We used freshly transformed E. coli cells (strain JM101Tr) in 
all expression experiments. This proved crucial to maintain a high expression level from the 
constitutive lpp promoter. For controlling expression levels, we performed  RNA “minipreps” 
on 5 ml overnight cultures grown in LB medium. We pelleted and resuspended cells in 50 µl 
of 10 mM Magnesium acetate, 1 mM Tris-HCl, pH 7.4 (Buffer L). We extracted the 
suspension with saturated phenol, ethanol precipitated the aqueous phase and analyzed the 
RNA contents analyzed by 8% polyacrylamide-urea gel electrophoresis. We visualized bands 
by UV shadowing. For large scale production (1 liter cultures), RNA accumulation was 
optimal after 12-18h of growth following inoculation, in the early stationary phase, and higher 
yields were obtained on richer media. We thus performed most cultures overnight in 2 x TY 
medium, starting from freshly transformed cells. As for minipreps, we pelleted and 
resuspended cells in 8 ml of buffer L. We added one volume of saturated phenol to the tube, 
which was gently agitated for one hour at room temperature, to ensure complete cell lysis. 
After centrifugation, we collected the aqueous phase and added 1/5 volume of 5 M NaCl to 
precipitate high molecular weight nucleic acids, which were then removed by centrifugation. 
We ethanol-precipitated the supernatant containing small RNA, allowed the pellet to dry and 
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then dissolved it in 20 mM sodium phosphate, pH 7.0 (Buffer A). We loaded the RNA extract 
on an ion-exchange column (Q-Hiload, Amersham) equilibrated in buffer A and eluted it with 
a 0 to 1 M NaCl gradient in the same buffer. We analyzed fractions by electrophoresis on 8% 
urea-acrylamide gels and pooled and ethanol-precipitated those containing the desired RNA. 
Yields were 10 to 50 mg of purified RNA per liter, with a purity of 80 to 90 %, depending on 
the construct, after this single chromatographic step. Whenever required, we could achieve 
further purification by gel filtration: we dissolved the RNA in 20 mM sodium phosphate, 100 
mM NaCl, pH 7.0, loaded it on a Superdex-75 column (Amersham) equilibrated in the same 
buffer and eluted it at 0.5 ml/min. We pooled and ethanol-precipitated fractions containing 
the RNA. For structural studies, we dissolved the purified RNA in water, dialyzed it and 
lyophilized it. 
NMR spectroscopy. We dissolved purified RNA samples in 300 µl of 10% 2H2O/90% H2O  
(final concentration 1 mM). We acquired spectra were at 15°C (288 K) on a 600 MHz Bruker 
Avance spectrometer. We recorded 1H- 15N TROSY and HMQC experiments as previously 
described31. 
Affinity purification. We pelleted an overnight culture (10 ml) of the overproducing strain. We 
suspended cells in 400 µL of 50 mM potassium phosphate, 5 mM MgCl2, 100 mM NaCl, 
pH 7.5 (Buffer A) and disrupted them by sonication. We removed debris by centrifugation 
and incubated the supernatant with either streptavidin-coated iron oxide magnetic beads 
(Dynal), or Sephadex G100 (Roche) suspended in buffer A. We washed the beads three times 
with buffer A and performed elution using 200 µL of  buffer A supplemented either with 5 
mM d-biotin or with 200 mg/ml of soluble dextran (Mr 1500, Fluka), for the strepatividin and 
sephadex aptamer constructs, respectively. 
Pull down assay. We extracted the tRNA chimera (tRNA/sephadex aptamer; 
tRNA/sephadex aptamer/23S rRNA) as described above (RNA "minipreps") and dissolved 
them in buffer A. We then incubated them with ribosomal protein L20C from E. coli (gift from 
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F. Allemand, IBPC, Paris) and sephadex G100 beads for 1 hour at 4 °C. We washed the 
beads three times with the same buffer. We eluted bound RNA and attached protein using 
200 mg/ml of soluble dextran (Mr 1500, Fluka) in the same buffer, transferred them into SDS 
gel loading buffer and electrophoresed them on a 12 % SDS–polyacrylamide gel. 
RNAse H cleavage. We purifeied recombinant, His-tagged E. coli RNAse H by Ni-NTA 
agarose and gel filtration chromatography. We first annealed the target RNA to the guide 
oligonucleotides in H2O (40 µM each, 1:1 ratio with the target RNA) by heating at 95°C for 
2 min. and cooled them down slowly to room temperature. We then added digestion buffer to 
a final concentration of 50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, pH 7.5. We started 
the cleavage reaction by adding 60 pmoles of E. coli RNase H per nmole of RNA, allowed it to 
proceed for 3h at 37°C and stopped it by ethanol precipitation. We purified preparative 
digests by ion-exchange chromatography (Mono-Q, Roche), under denaturing conditions (4M 
urea).  
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Figure legends  
Figure 1. The tRNA scaffold strategy. (a) Schematic structure of standard tRNA, showing 
some of the conserved tertiary interactions (thin lines). The scaffold used for inserting 
structured RNAs is boxed. (b) Cloning vectors used for expressing tRNA-RNA chimeras in E. 
coli. The anticodon stem is replaced by a a polylinker composed of unique EagI, EcoRV and 
SacII restriction sites. This specific combination of restriction sites ensures that the 
corresponding RNA transcript will fold into an anticodon-like stem and loop structure. (c) 
tRNA-RNA chimera with the epsilon sequence form human HBV virus (boxed) inserted into 
the human tRNALys3 scaffold. The cloning sites are grayed. (d) Purification profile of the 
tRNA-HBV chimera shown in panel c. E. coli transformed with the corresponding 
recombinant plasmid were grown overnight at 37°C in rich medium. Total small RNA were 
obtained after whole-cell phenol-extraction. This RNA extract fractionated on a Q-Hiload 
column, as described in Methods. Fractions were analyzed by urea-PAGE and RNA bands 
were visualized by UV shadowing. The leftmost lane corresponds to the total RNA extract 
and successive fractions are shown from left to right. Various E. coli tRNA eluted first, 
followed by small amounts of 5S ribosomal RNA, whereas the tRNA-HBV chimera eluted 
last, at an NaCl concentration of about 500 mM. After this single purification step, the tRNA 
chimera is ~90% pure, and the final yield is 50 mg/liter. 
Figure 2. Using tRNA chimeras in structural studies. 600 MHz NMR 1H-15N TROSY 
spectrum of the 15N-labeled tRNA-HBV epsilon chimera (inset) revealing the NH imino 
groups engaged in base pair hydrogen bonds. Selected peaks corresponding to the previously 
assigned tRNA scaffold and HBV epsilon moieties are labeled in black and red, respectively. 
Primed numbers correspond to the HBV epsilon numbering. The peak corresponding to s4U8 
(leftmost peak) is folded in the 15N dimension and its abnormal 15N shift (~179 ppm) is 
characteristic of the 4-thiolation of the base. Incorporation of pseudouridine Ψ55 is evidenced 
by the presence of a second imino group (N1), at a characteristic 15N chemical shift of 135.5 
(top right). Similar shifted resonances were observed for m7G46, T54 and dihydrouridines 
(not shown)  
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Figure 3. Structures of the several RNA chimera that were successfully expressed using the 
tRNA scaffold strategy. tRNALys3  derived constructs: (a) scaffold; (b) human HBV epsilon; (c) 
sephadex aptamer/human HBV epsilon; (d) E. coli 23S rRNA, 5’ region.  
Figure 4. Expression and purification of recombinant RNA. (a) Overexpression of various 
constructs. 1: tRNALys/HBV epsilon, 2: tRNALys/Sephadex aptamer/Duck HBV epsilon, 3 : 
tRNALys/Malachite green aptamer, 4: tRNAMet/Sephadex aptamer/HBV epsilon, 5: 
tRNALys/Sephadex aptamer/HBV epsilon, 6: tRNAMet/streptavidin aptamer/HBV epsilon, 
control: vector with no insert. Crude RNA minipreps were electrophoresed on an 8% 
polyacrylamide-urea gel and revealed by  UV shadowing. The white triangles indicate the 
overexpressed RNA band. tRNAMet based constructs (lanes 4 and6) were consistently slightly 
less expressed than the tRNALys based chimera (lanes 1-3 and 5). (b) Purification of a 
tRNAMet/sephadex aptamer chimera from a crude cell lysate under native conditions, using 
sephadex G100 beads, and soluble dextran for elution. (c) Pull-down assay. Two tRNA 
chimera were used, containing either the sephadex aptamer alone (control RNA), or the 
sephadex aptamer and helices 40 and 41 of E. coli 23S rRNA, which correspond to ribosomal 
protein L20 primary binding site (23S RNA). They were incubated with purified L20 and 
sephadex beads. Supernatant was removed, beads were washed with buffer and molecules 
bound were analyzed by SDS gel electrophoresis and proteins were visualized by coomassie 
staining. Both RNA chimera were bound (not shown), but only the 23S RNA chimera 
retained the L20 protein (white triangle). (d) Time course of RNAse H cleavage of the HBV 
RNA from the tRNALys scaffold (chimera shown in Fig. 3-A2), using "scissor" DNA 
oligonucleotides complementary to the tRNA scaffold. Control: untreated RNA chimera. 
Figure 5. NMR analysis of RNA inserts cleaved with RNAse H. (a) Structure of the tRNA-
16S rRNA A-site chimera that was expressed by growing cells in doubly 15N-13C labeled 
medium. The two “scissor” DNA oligonucleotides were 19-mers complementary to the 
scaffold nucleotides sidelined in grey. The RNAse H cleaving sites are indicated by blue 
triangles, they are located six nucleotides within the DNA oligonucleotide sequences. The 
16 
corresponding cleaved product is highlighted in yellow. (b) 1H-15N HMQC correlation 
spectrum of the cleaved and purified 16S rRNA A-site fragment, centered on the imino 
proton window. Spectral regions corresponding to A-U and G-C pairs are indicated and 
individual peaks are labeled with blue triangles. One A-U and ten to eleven G-C pairs are 
seen, in keeping with the secondary structure shown in panel (a). Additional resonances, 
corresponding to non-canonical pairs are indicated. 
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Supplementary Figure  1
Structure of the expression vector inserts. Shown are the DNA sequence tRNALys3
scaffold with the sephadex aptamer and the corresponding RNA sequence of processed transcript 
using the same color coding. Relevant restriction sites are indicated in yellow. Within the RNA 
transcript region, they were selected to maintain the appropriate 2D structure. 
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             Structures of the various RNA chimera that were successfully expressed using the tRNA 
scaffold strategy. (A) tRNALys3  derived constructs: 1, scaffold; 2, human HBV epsilon; 3, A. 
aeolicus tmRNA domain; 4, malachite green aptamer; 5, E. coli 16S ribosomal RNA decoding site; 6, 
HIV-1 dimerization initiation site; 7 sephadex aptamer; 8, streptavidin aptamer; 9, sephadex 
aptamer/human HBV epsilon, short construct; 10, sephadex aptamer/human HBV epsilon, long 
construct; 11, sephadex aptamer/duck HBV epsilon; 12, HCV IRES domain III; 13 bacteriophage 
phi29 pRNA; 14, E. coli 23S rRNA, 5’ region. (B) tRNAMet derived constructs: 1, scaffold; 2, 
sephadex aptamer; 3 streptavidin aptamer/human HBV epsilon.
Supplementary Figure  2
Malachite green aptamer function. (a) 2D structure of the chimera containing the 
malachite green aptamer. (b) Absorbance spectra of malachite green (green trace), malachite green 
with a non specific RNA chimera (tRNALys / HBV epsilon, black trace) and malachite green 
complexed with the specific aptamer RNA chimera. Concentration of the dye is the same in all three 
experiments. (c) Redshift of  the malachite green fluorescence in the presence of the specific RNA 
chimera: left cuvette, malachite green, right cuvette, malachite green complexed with the RNA 
chimera. The Kd of the dye for the RNA, measured by fluorescence titration, is 50 nM (not shown). 
Supplementary Figure  3
Dimerization of the tRNA chimera containing HIV-1 genomic RNA dimerization 
initiation site (DIS). The apparent RNA size was monitored by native polyacrylamide gel 
electrophoresis, using RNA minipreps. tRNALys/HBV epsilon chimera (left) was used as a control as it 
has the same size as the HIV-1 DIS chimera (110 bases vs 112 bases). The HIV-1 DIS chimera 
migrates as an RNA with an apparent size of ~200 bases, in keeping with the formation of a stable complex. 
Supplementary Figure  4
PAGE analysis of the cleavage product of a 16S rRNA A site . After purification,
the cleaved recombinant RNA was run alongside two oligonucleotide markers and the bands
were revealed by silver staining.
Supplementary Figure  5
chimera
Supplementary Table 
 
tRNALys derived constructs Length  (bases) 
yield 
 (mg per liter of 
culture) 
human HBV epsilon, short 
construct  (Suppl. Fig. 2A-2) 
 
110 21-50 
A. aeolicus tmRNA domain  
(Suppl. Fig. 2A-3) 
 
91 23 
malachite green aptamer 
(Suppl. Fig. 2A-4) 
 
105 20-25 
E.  coli 16S ribosomal RNA 
decoding site 
(Suppl. Fig. 2A-5) 
 
94 22 
HIV-1 dimerization  
initiation site 
(Suppl. Fig. 2A-6) 
 
104 16 
phage phi29 prohead RNA 
(Suppl. Fig. 2A-13) 184 22 
sephadex aptamer (Suppl. 
Fig. 2A-7) 115 20-25 
HCV IRES domain III 
(Suppl. Fig. 2A-12) 218 8 
sephadex aptamer/duck HBV 
epsilon 
(Suppl. Fig. 2A-11) 
159 10-15 
 
Overexpression yields of various tRNA chimera. Amounts were estimated from the 
UV absorbance (260 nm) of the purified recombinant products. 
